Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + thalidomide
- Development stage
- Phase 2
- Lead developer
- Baxter
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Cyclophosphamide** is an alkylating agent that works by inhibiting DNA replication, causing cell death, particularly in rapidly dividing cells like cancer cells[4]. **Thalidomide** acts as an immunomodulatory agent, affecting multiple pathways to inhibit cancer growth, including anti-angiogenic effects and immune system modulation[8]. Their combination is used in treating multiple myeloma, often alongside other drugs like dexamethasone.
- Other names
- CTD (when combined with dexamethasone)
02
Targets
CRBN (Cereblon)DNAIKZF1 (Ikaros family zinc finger protein 1)IKZF3 (Zinc finger protein Aiolos)NF-κB
Beyond the preview
Go deeper on cyclophosphamide + thalidomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + thalidomide.